Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

Roche recently launched two new analytical units, cobas c 703 and cobas ISE neo, enhancing their cobas pro integrated solutions platform for high-volume laboratories. These units address staffing shortages and space constraints faced by labs globally, emphasizing the importance of accurate and timely diagnostics in healthcare. The cobas c 703 boasts a high throughput of 2,000 tests per hour with 70 reagent positions, doubling the existing capacity on the cobas pro platform, increasing efficiency, and minimizing operator maintenance. The cobas ISE neo excels in ion selective electrode testing, achieving 1,800 tests per hour while featuring automated calibration and reduced manual intervention. It also minimizes waste and logistical efforts by running more tests per reagent bottle. Launched in 2018, the cobas pro integrated solutions platform is designed for high-volume clinical chemistry and immunochemistry testing. The system offers fast analysis, intelligent sample routing, short assay incubation times, automated maintenance, and reduced sample volume requirements. It aligns seamlessly with Roche's cobas pure integrated solutions, providing standardized results, operation, and minimal training needs, ideal for integrated healthcare networks. Roche's commitment to innovation is evident in its plans to integrate a mass spectrometry analyzer into the cobas pro integrated solutions soon. Founded in 1896, Roche, headquartered in Switzerland, has become a leading biotechnology company globally, specializing in in-vitro diagnostics and pharmaceuticals, dedicated to advancing personalized healthcare through scientific excellence and collaborations.